WallStreetZenWallStreetZen

NASDAQ: ADMA
Adma Biologics Inc Earnings Dates, Reports, Calls

OverviewForecastEarnings
RevenueDividendOwnership
Adma Biologics earnings were $209.4M for the trailing 12 months ending Sep 30, 2025, with 203.4% growth year over year. The latest ADMA earnings report on Sep 30, 2025 announced Q3 2025 earnings of $36.4M, up 6.5% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, ADMA reported annual earnings of $197.7M, with -800% growth. The next ADMA earnings date is Mar 19, 2026.

ADMA past earnings growth

How has ADMA's earnings growth performed historically?

Company
203.45%
Industry
59.6%
Market
54.41%
ADMA's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Industry Performance
ADMA's earnings have grown faster... subscribe to Premium to read more.
Earnings Growth vs Market Performance
ADMA's earnings growth is accelerating... subscribe to Premium to read more.
Accelerating Earnings Growth Performance

ADMA earnings history

Current Revenue
$488.6M
Current Earnings
$209.4M
Current Profit Margin
42.9%

ADMA Return on Equity

Current Company
54%
Current Industry
-21.2%
Current Market
35.1%
ADMA's Return on Equity (54%)... subscribe to Premium to read more.
High Return on Equity Performance

ADMA Return on Assets

Current Company
39.4%
Current Industry
-8.8%
ADMA is generating higher Return... subscribe to Premium to read more.
Above Average Return on Assets Performance

Be the first to know when ADMA announces earnings.

ADMA Return on Capital Employed

Current Company
32.05%
Current Industry
-3.5%
ADMA has gotten more efficient... subscribe to Premium to read more.
Increasing Return on Capital Employed Performance

ADMA vs Biotech Stocks

TickerEBITDAEarningsY/Y EarningsEPS
ADMA$172.13M$209.45M+203.45%$0.88
LGND$103.01M$48.58M+80.67%$2.31
ACLX-$242.23M-$217.90MN/A-$3.93
NAMS-$256.82M-$257.06MN/A-$2.38
VKTX-$236.95M-$237.39MN/A-$2.12
View Top Biotech Stocks

ADMA earnings dates

Next earnings date
Mar 19, 2026

Adma Biologics Earnings Reports & History FAQ

What were Adma Biologics's earnings last quarter?

On ADMA's earnings call on Invalid Date, Adma Biologics (NASDAQ: ADMA) reported Q3 2025 earnings per share (EPS) of $0.15, up 0% year over year. Total ADMA earnings for the quarter were $36.43 million. In the same quarter last year, Adma Biologics's earnings per share (EPS) was $0.15.

If you're new to stock investing, here's how to buy Adma Biologics stock.

When does Adma Biologics report earnings?

The next ADMA earnings date is Invalid Date. Add ADMA to your watchlist to be reminded of Adma Biologics's next earnings date.

Is Adma Biologics profitable or losing money?

As of the last Adma Biologics earnings report, Adma Biologics is currently profitable. Adma Biologics's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $209.45 million, a 207.41% increase year over year.

What was ADMA's earnings growth in the past year?

As of Adma Biologics's earnings date in Invalid Date, Adma Biologics's earnings has grown 203.45% year over year. This is 143.85 percentage points higher than the US Biotechnology industry earnings growth rate of 59.6%. ADMA earnings in the past year totalled $209.45 million.

What are Adma Biologics's earnings expectations?

The current EPS estimate for Adma Biologics's earnings report in Invalid Date is $0.19.
©2026 WallStreetZen
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletter
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.